A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

NCT05660265 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
11
Enrollment
INDUSTRY
Sponsor class

Stopped Sponsor decision to terminate the study due to strategic business consideration and not related to safety.

Conditions

Interventions

Sponsor

GlaxoSmithKline